Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Pfizer
This study was terminated on 13 Dec 2010 following a US FDA clinical hold for tanezumab osteoarthritis clinical studies which halted dosing and enrollment of patients on 23 June 2010 for potential safety issues.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
osteoarthritis of the knee or hip according to Kellgren-Lawrence x-ray grade of 2
You may not be if
pregnancy or intent to become pregnant
BMI greater than 39
other severe pain, significant cardiac, neurological or psychiatric disease
Clareo Health | Tanezumab In Osteoarthritis Of The Hip Or Knee
